The estimated Net Worth of Malcolm Hoenlein is at least $107 millier dollars as of 26 August 2020. Mr. Hoenlein owns over 16,667 units of Fortress Biotech Inc stock worth over $29,334 and over the last 9 years he sold FBIO stock worth over $0. In addition, he makes $78,000 as Independent Director at Fortress Biotech Inc.
Sign up
Mr. Hoenlein FBIO stock SEC Form 4 insiders trading
Malcolm has made over 1 trades of the Fortress Biotech Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 16,667 units of FBIO stock worth $300,006 on 26 August 2020.
The largest trade he's ever made was buying 16,667 units of Fortress Biotech Inc stock on 26 August 2020 worth over $300,006. On average, Malcolm trades about 667 units every 0 days since 2016. As of 26 August 2020 he still owns at least 16,667 units of Fortress Biotech Inc stock.
You can see the complete history of Mr. Hoenlein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Malcolm Hoenlein biography
Malcolm I. Hoenlein Ph.D serves as Independent Director of the Company. Mr. Hoenlein has served as a member of the Board of Directors since February 2014. Since 1986, Mr. Hoenlein has served as Chief Executive Officer and Executive Vice Chairman of the Conference of Presidents of Major American Jewish Organizations, the coordinating body on international and national concerns for 51 national American Jewish organizations. Previously, he served as the founding Executive Director of the Jewish Community Relations Council of Greater New York. Prior to that, he was the founding Executive Director of the New York Conference on Soviet Jewry. A National Defense Fellow at the Near East Center of the University of Pennsylvania, Mr. Hoenlein taught International Relations in the Political Science Department and served as a Middle East specialist at the Foreign Policy Research Institute. In addition, he served on the editorial staff of ORBIS, the Journal of World Affairs. He serves currently as a director of DarioHealth Corp, WellSense Technology, Delek Oil, and Nanox Technology. He previously served as a director for Eco-Fusion North America, Inc., and Powermat USA. Mr. Hoenlein has a B.A. in Political Science from Temple University and an M.A. in International Relations from the University of Pennsylvania, as well as an Hon. LL.D. from Touro College, an Hon. D.H.L. from Yeshiva University, an Hon. D.H.L. from Temple University and an Hon. D.H.L. from Bar Ilan University. Based on Mr. Hoenlein’s demonstrated sound business judgment and leadership and management experience, the Board of Directors believes that Mr. Hoenlein has the appropriate set of skills to serve as a member of the Board in light of the Company’s business and structure.
What is the salary of Malcolm Hoenlein?
As the Independent Director of Fortress Biotech Inc, the total compensation of Malcolm Hoenlein at Fortress Biotech Inc is $78,000. There are 11 executives at Fortress Biotech Inc getting paid more, with Robyn Hunter having the highest compensation of $1,798,070.
How old is Malcolm Hoenlein?
Malcolm Hoenlein is 76, he's been the Independent Director of Fortress Biotech Inc since 2014. There are no older and 11 younger executives at Fortress Biotech Inc.
What's Malcolm Hoenlein's mailing address?
Malcolm's mailing address filed with the SEC is C/O FORTRESS BIOTECH, INC., 1111 KANE CONCOURSE SUITE 301, BAY HARBOR ISLANDS, FL, 33154.
Insiders trading at Fortress Biotech Inc
Over the last 9 years, insiders at Fortress Biotech Inc have traded over $826,952 worth of Fortress Biotech Inc stock and bought 6,309,522 units worth $9,160,045 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss et George Avgerinos. On average, Fortress Biotech Inc executives and independent directors trade stock every 77 days with the average trade being worth of $271,550. The most recent stock trade was executed by Lindsay A Md Rosenwald on 11 July 2024, trading 5,000 units of FBIO stock currently worth $37,400.
What does Fortress Biotech Inc do?
fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
What does Fortress Biotech Inc's logo look like?
Complete history of Mr. Hoenlein stock trades at DarioHealth Corp, Fortress Biotech Inc et Fortress Biotech Inc
Fortress Biotech Inc executives and stock owners
Fortress Biotech Inc executives and other stock owners filed with the SEC include:
-
Robyn Hunter,
Chief Financial Officer, Treasurer, Secretary -
Michael Weiss,
Executive Vice Chairman - Strategic Development, Director -
Lindsay Rosenwald,
Executive Chairman of the Board, President, Chief Executive Officer -
Robyn M. Hunter,
CFO, Treasurer & Corp. Sec. -
Dr. Lindsay Allan Rosenwald,
Exec. Chairman, Pres & CEO -
Michael S. Weiss Esq.,
Vice Chairman & Exec. Vice Chairman of Strategic Devel. -
George Avgerinos,
Senior Vice President - Biologics Operations -
Eric Rowinsky,
Co-Vice Chairman and Director -
J. Jay Lobell,
Independent Director -
Dov Klein,
Independent Director -
Jimmie Harvey,
Independent Director -
Malcolm Hoenlein,
Independent Director -
Kevin Lorenz,
Independent Director -
Jaclyn Jaffe,
IR Contact Officer -
Dr. Thomas F. Schaible,
Project Leader of Inflammatory Bowel Disease -
David Jin,
Chief Financial Officer -
Lucy Lu,
Director